Prevalence and factors associated with chemotherapy-induced adverse events in cancer treatment centers in Amhara national regional state comprehensive referral hospitals, 2024: multicenter prospective follow up study Authors: Atalay Eshetie Demilie, Habtu Tsehayu Bayu, Mahder Metenu Taye, Fikadu Tadesse Diress, Endale Gebreegziabher Gebremedhn Published: 2025 ABSTRACT BackgroundChemotherapy drugs remain the gold standard treatment for cancer. However, the side effects limit chemotherapy treatment and make treatment outcome poor. This makes chemotherapy side effects a big public health problem globally.ObjectiveTo assess prevalence and factors associated with chemotherapy-induced adverse events in cancer treatment centers in Amhara national regional state comprehensive referral hospitals, Norwest Ethiopia 2024.MethodologyMulti-center prospective observational study was conducted. Data was collected using questionnaire and checklist. Adverse events were collected and graded using National Cancer Institute Common Terminology CTCAE version 4.0. Data was transformed from Epi data to SPSS and logistic regression analysis was done. Both crude and adjusted odds ratio were used to assess the strength of association. Variables with a p-value of less than 0.05 were considered as statistically significant.ResultsA total of 572 patients were included in the study with a response rate of 99.5%. The overall prevalence of chemotherapy related adverse events was 78.49% with (95%, CI = 0.7783–0.7817). Cisplatin causes adverse events in 152 (95%), oxaliplatin 59 (100%), paclitaxel 28 (100%), docetaxel 42 (76.4%), gemcitabine 68 (68%) patients, 5-Flurouracil 65 (51.2%) and cyclophosphamide 10 (29.4%) patients respectively. The commonest severe (grades 3–4) adverse events were peripheral neuropathy or pain (36.7%), nausea and vomiting (28.5%), hair loss (22.9%), fatigue (22%), itching (19.1%), cyanosis (18%), leukopenia (16.9%) and diarrhea (16.3%). Being female (AOR = 4.201, CI = 2.580–6.217), history of motion (AOR = 3.001, CI = 2.410–5.201), history of morning sickness (AOR = 1.610, CI = 101 − 3.1), second cycle chemotherapy (AOR = 2.701, CI = 201 − 8.09) and third cycle of chemotherapy (AOR = 3.201, CI = 2.91–5.302) were associated with chemotherapy related adverse events.Conclusion and recommendationsThe prevalence of chemotherapy-induced adverse events was high in the study settings. We recommend early cycle by cycle risk assessment of patients and management of adverse events. Additionally, training should be given for oncologic nurses about the risk assessment and management of adverse events. High emphasis should be given for patients who will receive oxaliplatin, cisplatin, paclitaxel, docetaxel and gemcitabine.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12885-025-15384-2. Introduction Chemotherapy drugs can damage healthy, fast-growing cells, such as the new blood cells in bone marrow, stomach, skin, hair and reproductive organs [1, 2]. Chemotherapy is the most effective and widely used treatment in most types of malignancies [1]. The most common reported side effects related with chemotherapy drugs are weakness, fatigue, nausea, hair loss, nausea vomiting and other side effects include mouth sores, dry mouth and numbness whereas diarrhea, abdominal cramps and memory impairment are less commonly occurring side effects [3]. Nausea and vomiting are common and feared symptoms among cancer patients, and up to 80% of patients will experience Chemotherapy induced nausea vomiting (CINV) without prophylactic therapy [4]. Chemotherapy induced nausea vomiting is also a frequent cause of patient non-adherence to chemotherapy, which may impact control of cancer and survival of patients [5].In the past three decades, more effective antiemetic medications were introduced and widely adopted [6]. The side effects of chemotherapy depend on the type of drug involved. Common side effects include infections, easy bruising or bleeding, and hair loss; because chemotherapy kills healthy immune cells, it can make a person more vulnerable to infection [7]. And because the immune system is weakened, any infections may last longer than usual [8]. Chemotherapy can cause a person to bruise or bleed more easily. Having chemotherapy experience this side effect, bleeding more heavily than usual can be dangerous [9]. The American Cancer Society (ACS) trusted source recommends contacting the cancer team immediately about any bleeding or unexplained bruising during cancer treatment or any blood in stool or urine [10]. Late chemotherapy side effects are temporary and disappear once treatment is over. Lately chemotherapy can cause long term changes in the body. Some of these changes may happen months or years after the treatment has finished; late side effects can include: early menopause, infertility, changes to feeling in your hands and feet (peripheral neuropathy), heart and lung problems [11]. Risk factors for chemotherapy related side effects are fall into patient-related, disease related and treatment-related categories. Patient-related risk factors include age younger than 50 years, female sex, poor performance status, history of light alcohol use (heavier drinkers have less emesis), a prior history of nausea 2 and/or vomiting associated with pregnancy or motion sickness, increased anxiety, a history of chemotherapy related complications with prior exposure to chemotherapy, and low social functioning [11, 12]. Chemotherapy induced neuropathic pain (CINP) is one of the commonest side effects [13]. It occurs within minutes of infusion of anticancer drugs and gets more frequent and worse with increasing treatment cycles. A systematic review revealed that acute neuropathy prolonged infusion times in 22% of patients, treatment delay (in 2% of patients), dose reduction in 14.5% patients; treatment cessation in 6–21% of patients and functional impairment in 43% patients [14]. Generally, adverse events are identified as the fifth leading cause of death and they constitute a major clinical problem in terms of human suffering and increased health care costs [15]. Chemotherapy induced adverse events affect chemotherapy treatment by prolonging drug infusion time, dose reduction, treatment delay, and treatment cessation [13, 14]. The aim of this study was to assess prevalence and factors associated with chemotherapy-induced adverse events in cancer treatment centers in Amhara national regional state comprehensive referral hospitals, Northwest Ethiopia 2024. Methods Study design and study period Multi-center prospective observational study was conducted from October 1, 2024 to February 30, 2025 in selected Amhara National Regional State comprehensive and specialized referral hospitals, Northwest Ethiopia. Study setting and period The study was conducted in three selected hospitals namely: University of Gondar comprehensive specialized hospital, Tibebe Ghion comprehensive specialized hospital and Felege hiwot comprehensive specialized hospital cancer centers which are located in Amhara Region Northwest Ethiopia. (1) University Gondar hospital: Is located in central Gondar administrative zone, Amara National Regional state. Know a day the University of Gondar comprehensive specialized hospital has its own cancer treatment center and on average 40 patients are admitted for chemotherapy treatment per month. (2) Felege hiwot referral comprehensive hospital: Found at Bahir Dar city which also has its own cancer treatment center and on average 30 patients are admitted for chemotherapy treatment per month. (3) Tibebe Ghion comprehensive specialized hospital: Found at Bahir Dar city which has its own cancer treatment center and according to hospital reports on average 45 patients are admitted for chemotherapy treatment per month. Study population All adult (≥ 18 years old) cancer patients admitted for evaluation and treatments of cancer during the study period. Inclusion and exclusion criteria Patients receiving chemotherapy and willing to participate in the study were included in the study On the other hand, patients, who are not mentally sound, have cognitive problem and those unable to record and who are not willing to participate in the study were excluded. Sample size and sampling technique To determine sample size, a single proportion formula will be used. By taking a proportion of 50% and assuming 95 confidence interval and 5% margin of error is considered, then the sample size calculated as \documentclass[12pt]{minimal} \usepackage{amsmath} \usepackage{wasysym} \usepackage{amsfonts} \usepackage{amssymb} \usepackage{amsbsy} \usepackage{mathrsfs} \usepackage{upgreek} \setlength{\oddsidemargin}{-69pt} \begin{document}$$n = \frac{(Z\frac{a}{2})^{2}\,p(1-p)}{d^{2}}$$\end{document} Where; n = is the desired sample size; z = is standard normal distribution usually set as 1.96 (corresponds to 95% confidence level); p = population proportion, d = marginal of error is 5% (0.05). n = 384 and adding 5% non-response rate, the final sample size for this study would be 404 (Fig. 1). Fig. 1Sample size allocations for each hospital Sample size allocations for each hospital Sampling technique All consecutive amputated patients who were available in those two selected comprehensive and specialized hospitals during the study period were included. Variables of the study Dependent variable Chemotherapy induced adverse event (yes/ no). Independent variables Age, sex, nutritional status, BMI, type of therapy, type of cancer, type of chemo regimen, presence of coexisting disease, alcohol consumption, morning sickness, motion sickness, history of smoking, stage of cancer, usage of anti-emetic drugs, site of cancer, metastasizes of cancer, cycle of chemotherapy (dose). Operational definitions Chemotherapy induced adverse events: are defined as side effects such as nausea and vomiting, diarrhea, peripheral neuropathy (pain), fatigue, leucopoenia, thrombocytopenia, anemia, hair loss, itching, rash, oral ulcer etc [3, 16]. Chemotherapy induced peripheral neuropathy: defined as abnormal sensations following chemotherapy such tingling, burning and cold induced pain in oropharyngeal, and upper and lower extremities (NCI-CTCAE version 4). Diarrhea: Increase of < 4 stools per day over baseline, mild increase in ostomy output compared to baseline (NCI-CTACE version 4). Vomiting: defined as forceful expulsion of orogastric contents through the mouth. Grade 1: 1–2 episodes (separated by 5 min) in 24 h; Grade2: 3–5 episodes (separated by 5 min) in 24 h; Grade3: >=6 episodes (separated by 5 min) in 24 h; tube feeding, TPN or hospitalization indicated and Grade 4: Life-threatening consequences; urgent intervention indicated (NCI-CTCAE version4). Fatigue: defined as feeling tired, weak or exhausted. Grade 1: fatigue relieved by rest. Grade 2: fatigue not relieved by rest; limiting instrumental activities of daily living and Grade 3: fatigue not relieved by rest; limiting self-care activities of daily living (CTCAE version 4). Leucopoenia: defined as a decrease in leucocytes count (< 4 × 109, NCI-CTCAE version 4). Thrombocytopenia: defined as a decrease in platelet count (< 75 × 103, NCI-CTACE version 4). Anemia: defined as hemoglobin < 10 g/dl (NCI-CTACE version 4). Hair loss: defined as ranging from minimal hair loss to non-reversible alopecia (NCI-CTACE version 4). Itching: refers to a sensation of discomfort and irritation that compels one to scratch. Rash: defined as bumps or redness on the skin. Oral ulcer: defined as loss or erosion of the delicate lining tissue of the mouth. History of motion sickness: defined as feeling of discomfort including nausea and vomiting when someone is in motion such as travelling by vehicles. History of morning sickness: defined as experience of unpleasant sensations in the morning such as nausea, loss of appetite and vomiting. Data collection Data collection was done using structured and pretested questionnaire and checklist (NCI-CTCAE, National Cancer Institute Common terminology Criteria for Adverse Events version4.0, see supplementary data). The structured questionnaire was filed by the data collector, using relevant information from the patient chart demographic data (sex, age, height, weight, BMI, stage of cancer, type of anti- cancer medication, cycle of anti-cancer medication) and direct observation (possible adverse events like, nausea, vomiting, diarrhea, hear loss, weight loss etc.,) and by asking patients (previous history of nausea and vomiting) at the cancer treatment centers. Data quality Data were collected by three trained data collectors guided by two supervisors. One day training was given for data collectors about by the principal and co investigators on the aim and objective of the study, how to approach study participants, how to use the questionnaire, on how to supervise and collect the data. Data collectors were supervised by investigators. The completeness of data were checked every day by the investigators. Data analysis Data were checked for completeness and entered into the Epi-Data version 4.6 software and transferred to SPSS version 26 for analysis. Descriptive statistics such as percentage and mean and median for continuous data were performed. The descriptive results were shown with mean and standard deviation for categorical data and median with interquartile range for continuous data. The normal distribution of continuous data was checked using the Shapiro-Wilk test. Both bivariable and multi variable logistic regression analysis were performed. The variables with p-value less than 0.2 from bivariable logistic regression were entered into the multivariable logistic regression. Multicollinearity is examined using the variance inflation factor (VIF = 1.014, p-value = 0.87). A Hosmer and Lemeshow test will use to evaluate the goodness-of-fit of the model (p-value = 0.68). Both crude and adjusted odds ratio with 95% CI were calculated to determine the strength of association between dependent and independent variables. The variables with p-value < 0.05 from multi-variable logistic regression analysis were considered statistically significant. Ethical consideration Ethical clearance was obtained from the institutional review board of the college of medicine and health science, School of Medicine, Bahir Dar University ethical review committee with ethical registration number of protocol number 003/2024). Permission letter was also obtained from other hospitals .Oral informed consent was obtained from each study subject after a clear explanation during the preoperative period about the objective, purpose and as they have the right to refuse to participate in the study. Confidentiality was ensured by avoiding personal identifiers and locking the questionnaire and checklist. Results Socio-demographic characteristics of the study participants A total of 575 patients who received chemotherapy treatment at cancer treatment centers during the study period. However, 3 patients were excluded due to incomplete data. Therefore, a total of 572 patients were included in the study with a response rate of 99.5%. Of 572 patients, 223 (39%) were from Tibebe Ghion specialized hospital, 199 (34.8%) were from university of Gondar hospital and 150 (26.2%) patients from Felege hiwot specialized hospital respectively (Table 1). Among the participants, 351 (62.4%) patients were females and 221 (38.6%) were males. The average age of the study participants was 45.05 ± 15.09, with the majority (60%) were above 35 years old (Table 1). Table 1Factors related with patients (N = 572)VariablesCategoryFrequency (n)Percentage (%)SexFemale35162.4%Male22138.6%Age19–2515126.426–3919333.740–5911319.760–706511.4> 70508.7BMI< 18.532857.3%18.5–24.924442.7%History of coexisting diseaseYes8114.2%No49185.8%History of alcohol consumptionYes11119.4%No46180.6%History of smokingYes10919.1%No46380.9%History of motion sicknessYes20335.5%No36964.5%History of morning sicknessYes11920.8%No45379.2% Table 1Factors related with patients (N = 572)VariablesCategoryFrequency (n)Percentage (%)SexFemale35162.4%Male22138.6%Age19–2515126.426–3919333.740–5911319.760–706511.4> 70508.7BMI< 18.532857.3%18.5–24.924442.7%History of coexisting diseaseYes8114.2%No49185.8%History of alcohol consumptionYes11119.4%No46180.6%History of smokingYes10919.1%No46380.9%History of motion sicknessYes20335.5%No36964.5%History of morning sicknessYes11920.8%No45379.2% Factors related with patients (N = 572) Factors related with patients The majority of study participants have no history of coexisting disease (n = 491, 85.8%) (Table 1). Additionally, the majority of study participants have not history of alcohol consumption (n = 461, 80.6%). Only 19.4% of patients have alcohol consumption history. The majority of study participants were non-smokers (n = 463, 80.9%). Only 203 (35.5%) has history of motion sickness. Additionally, most patients (n = 463, 80.9%) have no history of morning sickness (Table 1). Factors related with cancer and chemotherapy regimens Sarcoma was the most common type of cancer in our study (n = 256, 44.7%) followed by carcinoma 252 (44.1%). In contrast, Leukemia and lymphomas were not common 41 (7.2%) and 23 (4%) respectively. The majority of cancers were stage II (n = 287, 50.2%) and stage I (n = 141, 24.7%) respectively (Table 2). Breast and cervical cancer were the most common with prevalence of 113 (19.8%) and 100 (17.5%) respectively. Only 12 (2.1%) patients had distance metastasis (Table 2). A large numbers of patients received their first cycle (n = 206, 36%) and second cycle chemotherapy (n = 271, 47.4%) respectively (Table 3). Cisplatin and 5-Flurouracil were the most frequently used anti-cancer drugs followed by Gemcitabine and oxaliplatin respectively. Only 561 (98%) patients received radiotherapy. Most patients were given single anti-emetics during chemotherapy (n = 287, 50.2%); whereas double and triple anti-emetics usage were less common (n = 180, 31.5%) and (n = 105, 18.3%) respectively (Table 2). Table 2Factors related with cancer features (N = 572)VariablesCategoryFrequency (n)Percentage (%)Type of cancerCarcinomas25244.1%Leukemias417.2%Lymphomas234%Sarcomas25644.7%Stage of cancerStage I14124.7Stage II28750.2Stage III13223.1%Stage IV122.1%Type of cancerBreast Cancer11319.8%Cervical cancer10017.5Gestational Trophoblastic8815.4%Disease Urinary Bladder cancer193.3%Carcinoma of gastro-intestine7613.3%Carcinoma of thyroid376.5%Prostrate Carcinoma5910.3%Carcinoma Gall Bladder152.6%Soft Tissue Sarcoma457.9%Acute Lymphoblastic leukemia122.1%Others50.9%Is the cancer metastasisYes122.1No56097.9%Cycle of chemotherapyFirst cycle20636%Second cycle27147.4%Third cycle9516.6%Radiotherapy historyYes56198%No112%Types of chemotherapy (drugs)Cisplatin15927.8%5-Flurouracil12722.2%Gemcitabine10017.5%Cyclophosphamide345.9%Docetaxel559.6%Oxaliplatin5910.3%Paclitaxel284.9%Others101.7%Use of anti-emetic drugsSingle anti-emetics (dexamethasone)28750.2%Double anti-emetics (dexamethasone & ondansetron)18031.5%Triple anti-emetics (dexametason, ondansetron and metoclopramide)10518.3% Table 2Factors related with cancer features (N = 572)VariablesCategoryFrequency (n)Percentage (%)Type of cancerCarcinomas25244.1%Leukemias417.2%Lymphomas234%Sarcomas25644.7%Stage of cancerStage I14124.7Stage II28750.2Stage III13223.1%Stage IV122.1%Type of cancerBreast Cancer11319.8%Cervical cancer10017.5Gestational Trophoblastic8815.4%Disease Urinary Bladder cancer193.3%Carcinoma of gastro-intestine7613.3%Carcinoma of thyroid376.5%Prostrate Carcinoma5910.3%Carcinoma Gall Bladder152.6%Soft Tissue Sarcoma457.9%Acute Lymphoblastic leukemia122.1%Others50.9%Is the cancer metastasisYes122.1No56097.9%Cycle of chemotherapyFirst cycle20636%Second cycle27147.4%Third cycle9516.6%Radiotherapy historyYes56198%No112%Types of chemotherapy (drugs)Cisplatin15927.8%5-Flurouracil12722.2%Gemcitabine10017.5%Cyclophosphamide345.9%Docetaxel559.6%Oxaliplatin5910.3%Paclitaxel284.9%Others101.7%Use of anti-emetic drugsSingle anti-emetics (dexamethasone)28750.2%Double anti-emetics (dexamethasone & ondansetron)18031.5%Triple anti-emetics (dexametason, ondansetron and metoclopramide)10518.3% Factors related with cancer features (N = 572) Prevalence of chemotherapy related adverse events The overall prevalence of chemotherapy induced adverse events was 78.49% with (95%, CI = 0.7783–0.7817). Cisplatin causes adverse events in 152 out of 159 patients (95%), oxaliplatin in all 59 (100%) patients, paclitaxel in all 28 (100%) patients, docetaxel 42 out of 55 (76.4%) patients, gemcitabine 68 out of 100 (68%) patients, 5-Flurouracil 65 out of 127 (51.2%) patients and cyclophosphamide 10 out of 34 (29.4%) patients respectively. Of expected chemotherapy-induced adverse events, nausea and vomiting was highly prevalent 76.7% with (95%, CI = 74.01–85.9) followed by peripheral neuropathy (pain) 66.4% (95%, CI = 64.01–75.9). Additionally, chemotherapy-induced hair loss 58.4% (95%, CI = 54.01–65.9), itching 56.5% (95%, CI = 53.01–61.7) and fatigue 53.8% (95%, CI = 48.01–55.8) were occurred above 50%. Whereas chemotherapy-induced adverse events with prevalence below 50% were leucopenia 49.7% with (95%, CI = 43.01–51.7), diarrhea 49.1% (95%, CI = 45.1–53.2), cyanosis 48.4% (95%, CI = 44.01–51.9), rash 42.1% (95%, CI = 35.71–46.9), anemia 35% with (95%, CI = 32.01–41.9), thrombocytopenia 33.7% (95%,CI = 31.11–37.37) and oral ulcer 37.9% with(95%,CI = 34.3-47.37) (Table 3). Table 3Prevalence chemotherapy related adverse events using NCI-CTCAE (N = 572)Type of adverse eventNo adverse eventn (%)Grade 1n (%)Grade2n (%)Grade 3n (%)Grade 4n (%)Grades 1–2n (%)Grades 3–4n (%)Nausea and vomiting133 (23.3)128 (22.4)148 (25.8)122 (21.3)41 (7.2)276 (48.3)163 (28.5)Hair loss238 (41.6)98 (17.1)105 (18.4)87 (15.2)44 (7.7)203 (35.5)131 (22.9)Peripheral neuropathy (pain192 (33.6)95 (16.6)75 (13.1)110 (19.2)100 (17.5)170 (29.7)210 (36.7)Leucopenia288 (50.3)121(21.2)96 (16.8)36 (6.3)31 (5.4)217 (37.9)97 (16.9)Fatigue264 (46.2)104 (18.2)78 (13.6)126 (22)182 (31.8)126 (22)Diarrhea291 (50.9)102 (17.8)86 (15)48 (8.4)45 (7.9)188 (32.7)93 (16.3)Rash331 (57.9)94 (16.4)78 (13.6)36 (6.3)33 (5.8)172 (30.1)69 (12.1)Cyanosis295 (51.6)106 (18.5)68 (11.9)55 (9.6)48 (8.4)174 (30.4)103 (18)Anemia372 (65)76 (13.3)65 (11.4)38 (6.6)21(3.7)141 (24.7)59 (10.3)Thrombocytopenia379 (66.3)73 (12.8)61 (10.7)35 (6.1)24 (4.2)134 (23.4)59 (10.3)Oral ulcer355 (62.1)84 (14.7)78 (13.6)36 (6.3)19 (3.3)162 (28.3)55 (9.6)Itching249 (43.5)116 (20.3)98 (17.1)76 (13.3)33 (5.7)214 (37.4)(19.1) Table 3Prevalence chemotherapy related adverse events using NCI-CTCAE (N = 572)Type of adverse eventNo adverse eventn (%)Grade 1n (%)Grade2n (%)Grade 3n (%)Grade 4n (%)Grades 1–2n (%)Grades 3–4n (%)Nausea and vomiting133 (23.3)128 (22.4)148 (25.8)122 (21.3)41 (7.2)276 (48.3)163 (28.5)Hair loss238 (41.6)98 (17.1)105 (18.4)87 (15.2)44 (7.7)203 (35.5)131 (22.9)Peripheral neuropathy (pain192 (33.6)95 (16.6)75 (13.1)110 (19.2)100 (17.5)170 (29.7)210 (36.7)Leucopenia288 (50.3)121(21.2)96 (16.8)36 (6.3)31 (5.4)217 (37.9)97 (16.9)Fatigue264 (46.2)104 (18.2)78 (13.6)126 (22)182 (31.8)126 (22)Diarrhea291 (50.9)102 (17.8)86 (15)48 (8.4)45 (7.9)188 (32.7)93 (16.3)Rash331 (57.9)94 (16.4)78 (13.6)36 (6.3)33 (5.8)172 (30.1)69 (12.1)Cyanosis295 (51.6)106 (18.5)68 (11.9)55 (9.6)48 (8.4)174 (30.4)103 (18)Anemia372 (65)76 (13.3)65 (11.4)38 (6.6)21(3.7)141 (24.7)59 (10.3)Thrombocytopenia379 (66.3)73 (12.8)61 (10.7)35 (6.1)24 (4.2)134 (23.4)59 (10.3)Oral ulcer355 (62.1)84 (14.7)78 (13.6)36 (6.3)19 (3.3)162 (28.3)55 (9.6)Itching249 (43.5)116 (20.3)98 (17.1)76 (13.3)33 (5.7)214 (37.4)(19.1) Prevalence chemotherapy related adverse events using NCI-CTCAE (N = 572) The commonest severe (grades 3–4) adverse events were peripheral neuropathy or pain (36.7%), nausea and vomiting (28.5%), hair loss (22.9%), fatigue (22%), itching (19.1%), peripheral cyanosis (18%), leukopenia (16.9%) and diarrhea (16.3%) (Table 3). Factors associated chemotherapy induced adverse events The variables that had a p value of less than 0.2 from bivariable logistic regression include sex, age, history of motion sickness, history of morning sickness, alcohol consumption history, smoking history, presence of coexisting diseases, metastasis of cancer, nutritional status of the patients, cycle of chemotherapy, usage of anti-emetics before chemotherapy, types of chemotherapy drugs, types of cancer and stage of cancer, cummulative dose. Among those sex, patients who has history of motion sickness, patients who has history of morning sickness, cycles of chemotherapy and usage of anti-emetics during chemotherapy had significant association with chemotherapy induced adverse events from the multi variable logistic regression with p value < 0.05 (Table 4). Table 4Factors associated with prevalence of chemotherapy induced adverse events (N = 572)VariablesChemotherapy induced adverse eventsCOR(95% CI)AOR ( 95% C.I)P valueYes (n)No (n)sexFemale275(78.4%)76(21.6%)5.8(4.04–7.705)4.201(2.58–6.217)0.0001Male85(38.5%)136(61.5%)(1)History of motion sicknessYes151(74.4%)52(25.6%)4.6(3.331–6.902)3.001(2.41–5.201)0.0027No143(38.8%)226(61.2%)(1)History of morning sicknessYes90(75.6%)29(24.4%)6.15(3.23–8.9)1.61(1.01–3.1)0.00128No152(33.6%)301(66.4%)(1)Cycles of chemotherapy1st cycle166(80.6%)40(19.4%)(1)2nd cycle137(50.6%)134(49.4%)4.06(2.07–5.025)2.7(2.01–4.09)0.01243rd cycle50(52.6%)45(47.4%)3.74(2.03–6.001)3.201(2.11–5.302)0.00024Usage ofanti-emetics drugsSingle200(72.6%)87(27.4%)(1)Double801000.84(0.523–0.851)0.76(0.476–0.778)0.0012Triple25(34.9%)80(65.1%)0.997(0.71-0.9998)0.98(0.704–9.991)0.00022Key; COR Crude Odds Ratio, AOR Adjusted Odds Ratio, C.I Confidence Interval Table 4Factors associated with prevalence of chemotherapy induced adverse events (N = 572)VariablesChemotherapy induced adverse eventsCOR(95% CI)AOR ( 95% C.I)P valueYes (n)No (n)sexFemale275(78.4%)76(21.6%)5.8(4.04–7.705)4.201(2.58–6.217)0.0001Male85(38.5%)136(61.5%)(1)History of motion sicknessYes151(74.4%)52(25.6%)4.6(3.331–6.902)3.001(2.41–5.201)0.0027No143(38.8%)226(61.2%)(1)History of morning sicknessYes90(75.6%)29(24.4%)6.15(3.23–8.9)1.61(1.01–3.1)0.00128No152(33.6%)301(66.4%)(1)Cycles of chemotherapy1st cycle166(80.6%)40(19.4%)(1)2nd cycle137(50.6%)134(49.4%)4.06(2.07–5.025)2.7(2.01–4.09)0.01243rd cycle50(52.6%)45(47.4%)3.74(2.03–6.001)3.201(2.11–5.302)0.00024Usage ofanti-emetics drugsSingle200(72.6%)87(27.4%)(1)Double801000.84(0.523–0.851)0.76(0.476–0.778)0.0012Triple25(34.9%)80(65.1%)0.997(0.71-0.9998)0.98(0.704–9.991)0.00022Key; COR Crude Odds Ratio, AOR Adjusted Odds Ratio, C.I Confidence Interval Factors associated with prevalence of chemotherapy induced adverse events (N = 572) Usage of anti-emetics drugs Key; COR Crude Odds Ratio, AOR Adjusted Odds Ratio, C.I Confidence Interval Multivariable logistic regression analysis showed that being female were 4.2 times more likely risky to develop chemotherapy induced adverse events as compared to males with (AOR = 4.201,CI = 2.580–6.217). Having history of motion sickness increase the prevalence of chemotherapy related adverse events by three times as compared those who has not history of motion sickness with (AOR = 3.001, CI = 2.410–5.201). Additionally, having history of morning sickness increase chemotherapy related complications by 1.61 times as compared to those who has not history of morning sickness with (AOR = 1.610, CI = 1.01–3.1 ). As the cycle of chemotherapy increase chemotherapy adverse events also likelihoods increase, in third cycle of chemotherapy adverse events increase by 3.2 times as compared to first cycle of chemotherapy with (AOR = 3.201,CI = 2.11–5.302) and in second cycle chemotherapy adverse events increases by 2.7 times as compared to first cycles of chemotherapy with (AOR = 2.701,CI = 2.01–8.09). Additionally, usage of double regimen of anti-emetic drugs during chemotherapy decreased the occurrence of chemotherapy related adverse events by 24% as compared to single anti-emetics with (AOR = 0.76, CI = 0.476–0.778) and usage of triple regimen of anti-emetic drugs during chemotherapy decreased the occurrence of chemotherapy related adverse events by 2% as compared to single anti-emetics with (AOR = 0.98, CI = 0.704–9.991) (Table 4). Discussion Chemotherapy, either in alone or in combination, continues to be the cornerstone treatment for the majority of human cancers. However, there is still a significant burden of chemotherapy-associated adverse events, which are linked to significant morbidity, mortality, and expenses that impact patients in a variety of ways, including their ability to function physically, emotionally, and socially [17]. This study showed that the prevalence of chemotherapy induced adverse events at chemotherapy treatment centers in Amhara National Regional Sate comprehensive and specialized hospitals cancer treatment center was 78.43% (95%, CI = 42.07–57.31). This finding was high compared with the study done in France at cancer treatment center where the prevalence of chemotherapy induced adverse events was 44.5% [18]. The discrepancy could be due to less adjuvant therapy in our study settings. On the other hand, our finding is low as compared with study done in Australia incidence of self-reported chemotherapy side effects was 80% [19]. This discrepancy could be due to the difference in educational level of patients and tools used for assessment of adverse events. In our study, nausea and vomiting, peripheral neuropathy (pain), itching and fatigue were highly prevalent. Nausea and vomiting was highly prevalent in our study (76.7%). This finding is supported by study done by C. M. Teunissen et al. in Netherlands [20]. This is because chemotherapy causes variety of peripheral and central inputs known as the peripheral and central pathways, respectively, and elicits the emetic reflex as a response. The peripheral pathway originates in the gastrointestinal tract, where stimuli such as pharyngeal stimulation or gastric/duodenal distension are transmitted via the abdominal vagal afferents [21]. Additionally, the prevalence of peripheral neuropathy (pain) was high in our study (66.4%). This finding is in line with a study done in Scotland, UK 68.1% [22]. Chemotherapy-induced neuropathy is one of the most common adverse events of chemotherapy that affects negatively chemotherapy treatment in 65–85% of patients and makes treatment outcome poor [13, 14]. Moreover, chemotherapy-induced hair fall (loss) was 58.4% in our study. This is supported by Trüeb et al. in France the incidence of chemotherapy-induced hair loss was 65% [23]. This study found that female patients were more risky to develop chemotherapy induced adverse events during chemotherapy as compared to male patients with (AOR = 4.201, CI = 2.580–6.217). This finding aligns with previous research suggesting that women may be more susceptible to certain types of chemotherapy induced adverse events particularly nausea and vomiting [24, 25]. This difference may be attributed to hormonal factors, variations in drug metabolism, or differences in body composition [24]. This implies that clinicians should be aware of the increased risk of chemotherapy induced adverse events in female patients and incorporate this knowledge into their risk assessment and treatment planning. Proactive management strategies should be implemented to minimize the risk of chemotherapy induced adverse events in female patients. Female patients should be educated about the potential increased risk of chemotherapy induced adverse events and the importance of reporting any symptoms promptly. This study also found that patients with a history of motion sickness were three times more likely to experience chemotherapy induced adverse events compared to those without this history (AOR = 3.001, CI = 2.410–5.201). This finding is supported by a study done by Morrow et al. ND Tsuji et al. in United States of America and Japan [26, 27]. This could be due to a heightened sensitivity of the vestibular system or a lower threshold for triggering the vomiting reflex [27]. This finding suggests that individuals with a predisposition to motion sickness may be more sensitive to the emetogenic effects of chemotherapy drugs. This indicates that close monitoring for chemotherapy induced adverse events is essential throughout the course of chemotherapy. This includes regular assessment of symptoms, prompt intervention for any adverse events, and adjustments to treatment plans as needed. Additionally, this study revealed that patients with a history of morning sickness were 1.61 times more likely to experience chemotherapy induced adverse events compared to those without this history (AOR = 1.610, CI = 1.01–3.1). Potentially due to similar underlying mechanisms as motion sickness [27]. This could involve exploring the accumulation of drug-induced damage to the gastrointestinal tract or other organs, changes in immune function, or alterations in DNA repair mechanisms [28]. This finding suggests that clinicians should be aware of this association and incorporate it into their risk assessment for patients undergoing chemotherapy and aggressive anti-emetic prophylaxis should be implemented, potentially using stronger anti-emetic regimens or starting anti-emetic therapy earlier in the treatment course. This study found a significant increase in the likelihood of chemotherapy induced adverse events with each subsequent cycle of chemotherapy. Specifically, the risk of chemotherapy induced adverse events was 3.2 times higher in the third cycle compared to the first cycle (AOR = 3.201, CI = 2.11–5.302) and 2.7 times higher in the second cycle compared to the first cycle (AOR = 2.701, CI = 2.01–8.09). This could involve exploring the accumulation of drug-induced damage to the gastrointestinal tract, dorsal root ganglia neurons or other organs, changes in immune function, or alterations in DNA repair mechanisms [28]. This finding highlights the cumulative effect of chemotherapy on the body, leading to increased susceptibility to adverse events with repeated exposure and this result was supported by other studies [29, 30]. Clinicians should be aware of the increasing risk of chemotherapy induced adverse events with each cycle and implement more frequent monitoring for adverse events, particularly during later cycles. This includes regular assessment of symptoms, prompt intervention for any adverse events, and adjustments to treatment plans as needed. This study showed that the use of double or triple anti-emetic regimens during chemotherapy significantly reduced the occurrence of chemotherapy induced adverse events compared to single anti-emetic regimens. Double regimens reduced the risk by 24% (AOR = 0.76, CI = 0.476–0.778), while triple regimens reduced the risk by 2% (AOR = 0.98, CI = 0.704–9.991). This finding underscores the importance of aggressive anti-emetic prophylaxis in managing chemotherapy induced adverse events, particularly in patients with risk factors [31, 32]. Risk assessment should include inquiries about history of motion sickness, morning sickness, and other potential risk factors for chemotherapy induced adverse events. This can help to identify patients at higher risk and guide the selection of appropriate anti-emetic regimens. Close monitoring for chemotherapy induced adverse events is essential throughout the course of chemotherapy, especially during later cycles. Early intervention and appropriate management strategies can help minimize the impact of these adverse events on patient well-being and treatment adherence. Strength and limitation of the study The strengths of this study lies on its observational study, multicenter and large sample size. The limitation of this study is that we did not collect data beyond third cycle due to financial constraints. Additionally, we did not report the numbers of patients who developed adverse events in the first cycle also developed adverse events in the subsequent cycles. Conclusions and recommendations The prevalence of chemotherapy-induced adverse effects was high in the study settings. Female gender, history of motion, history of morning sickness and increase in the number of treatment cycles (second cycle & third cycle) had strong association with the development of chemotherapy-induced adverse events. We recommend early cycle by cycle risk assessment of patients and management of adverse events. Additionally, training should be given for oncologic nurses about the risk assessment and management of adverse events. Moreover, high emphasis should be provided for patients who will be receiving oxaliplatin, cisplatin, paclitaxel, docetaxel, and gemcitabine. Supplementary Information Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.